Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

Launched by BAHRIA UNIVERSITY · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the effectiveness and safety of four different medication combinations for people with newly diagnosed Type 2 Diabetes. The medications being studied are Glimepiride, Empagliflozin, and Sitagliptin, all used alongside Metformin. The goal is to find out which combination works best to help control blood sugar levels and to see how safe each treatment is. The study will include 172 participants aged between 30 and 55 years at the National Medical Centre in Karachi, Pakistan.

To be eligible for this trial, participants must be between 30 and 55 years old, have a specific level of blood sugar (HbA1c) between 8.5 and 10 mmol/mol, and have a body mass index (BMI) between 18.5 and 29.9. Participants will take one of the medication combinations daily for 90 days, and their progress will be closely monitored through blood sugar checks and other health measurements at the beginning of the study and again at 6 weeks and 12 weeks. This study is currently recruiting and offers a chance to contribute to important diabetes research while receiving medical supervision.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and females
• • Age 30-55yrs
• • HbA1c = ≥ 8.5 \<10 mmol/mol (ADA. 2018)
• • BMI \>18.5- \<29.9 (WHO Asian Criteria)
• • Treatment naïve patients
• • With / without dyslipidemia.
• Exclusion Criteria:
• • HbA1c \>10 mmol/mol
• • BMI \> 30
• • Pregnancy or lactation
• • Systemic diseases such as: hypertension, thyroid, liver, renal diseases etc.
• • Known allergy or intolerance to Metformin, Glimepiride, Sitagliptin or Empagliflozin.